Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00401271|
Recruitment Status : Completed
First Posted : November 20, 2006
Last Update Posted : March 7, 2007
The purpose of this trial is to evaluate the safety, efficacy and pharmacokinetics of 100mg, 200mg , 300mg and 400mg once daily of OPC-67683, administered orally for 14 consecutive days, in patients with uncomplicated, smear-positive pulmonary TB.
The four OPC-67683 treatment groups will comprise 12 patients each and the one standard therapy (Rifafour e-275) group six patients.
Trial 242-06-101 is an exploratory and not a confirmatory trial and as such no hypothesis will be tested statistically.
The control group, six patients treated with Rifafour, will serve as an control to confirm the microbiological assessments during the trial.
|Condition or disease||Intervention/treatment||Phase|
|Pulmonary Tuberculosis||Drug: OPC-67683 Drug: Rifafour e-275||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||54 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Four Oral Doses of OPC-67683 in Patients With Uncomplicated, Smear-Positive, Pulmonary Tuberculosis|
|Study Start Date :||November 2006|
|Estimated Study Completion Date :||March 2007|
- TB bacterial load in sputum measured as colony forming units
- Early Bactericidal Activity (EBA)
- Slope 0-14
- Tme to culture positivity
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00401271
|Tiervlei Trial Center, Karl Bremer Hospital|
|Bellville, W Cape, South Africa, 7531|
|University of Cape Town Lung Institute|
|Mowbray, W Cape, South Africa, 7700|
|Medical Research Council|
|Durban, South Africa, 4000|
|Principal Investigator:||Andreas H Diacon, Dr.||Tiervlei Trial Center|
|Principal Investigator:||Roxana Rustomjee, Dr.||Medical Research Council|
|Principal Investigator:||Rodney Dawson, Dr.||University of Cape Town Lung Institute|